BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
biote Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.08−0.00 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $30.92M
- P/E (TTM)
- 10.8
- Dividend yield
- –
Share price
−$1.76 (−61.97%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
biote Corp. saw revenue fall 7.8% to $183.53M over the twelve months to Jun 30, 2026. Operating income fell 58.3% to $14.75M, moving the operating margin from 17.8% to 8.0%. Free cash flow was $19.87M, down 42.9% from a year earlier.
Revenue
$183.53M
-7.8% vs. a year earlier
Operating income
$14.75M
-58.3% vs. a year earlier
Free cash flow
$19.87M
-42.9% vs. a year earlier
EPS, diluted
$0.10
-88.9% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $30.92M
- P/E ratio
- 10.8
- Price to sales
- 0.17
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 64.28%
Fundamentals
- Revenue
- $183.53M
- Net income
- $5.86M
- EPS, diluted
- $0.10
- Free cash flow
- $19.87M
- Book value per share
- -$2.30
- Diluted shares
- 29M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$183.53M-7.8% YoY
Gross profit
$125.86M-12.2% YoY
Operating income
$14.75M-58.3% YoY
Net income
$5.86M-81.3% YoY
EPS, diluted
$0.10-88.9% YoY
Free cash flow
$19.87M-42.9% YoY
Reported periodTrailing twelve months